GlassScriptPhysician profile
Thomas H Graham
NPI 1508860990
$2,054.14
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $936 · 2020: $620 · 2021: $146 · 2022: $67.71 · 2023: $182 · 2024: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $285.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $185.27 | 2019-2020 | |
| Abbvie INC. | $181.89 | 2023 | |
| Lilly USA, LLC | $171.58 | 2019-2020 | |
| Celgene Corporation | $151.14 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $135.56 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $134.20 | 2019-2020 | |
| Biogen, INC. | $118.10 | 2020 | |
| Sk Life Science, INC. | $103.57 | 2024 | Xcopri |
| E.R. Squibb & Sons, L.L.C. | $91.17 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $74.42 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $61.76 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $56.97 | 2019 | |
| Assertio Therapeutics, INC. | $51.85 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $44.91 | 2019 | |
| Ucb, INC. | $42.83 | 2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $42.79 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.54 | 2020 | |
| Acorda Therapeutics, INC | $38.41 | 2019 | |
| Amneal Pharmaceuticals LLC | $36.00 | 2019-2020 | |
| Allergan, INC. | $35.83 | 2019-2020 | |
| Amgen INC. | $34.16 | 2019 | |
| Emd Serono, INC. | $33.62 | 2019 | |
| Csl Behring | $29.87 | 2020 | |
| Bausch Health US, LLC | $24.61 | 2019 | |
| Xeris Pharmaceuticals, INC. | $22.51 | 2022 | |
| Mallinckrodt Hospital Products INC. | $20.68 | 2020 | |
| Tanabe Pharma America, INC. | $19.87 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $19.28 | 2020 | |
| Acadia Pharmaceuticals INC | $13.80 | 2019 | |
| Pfizer INC. | $13.52 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.27 | 2019 | |
| Akcea Therapeutics, INC. | $11.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.